Quick Take: Finding oversold stock opportunities requires identifying high-quality companies experiencing temporary sell-offs while technical indicators reach extreme lows. By combining momentum signals—such as RSI dipping below 30, MACD momentum shifts, and Williams %R falling below -80—investors can enter high-conviction positions in top-tier companies like AbbVie (ABBV), Bristol Myers Squibb (BMY), and Enbridge (ENB) at steep valuation discounts.
The Psychology of Market Panic: Why Fear Creates Excessive Mispricing
Some of the best opportunities can be found in beaten-down oversold stocks.
Especially when there’s still a good amount of fear.
Remember, crises often create opportunities, as we’ve learned from some of the richest investors. Warren Buffett, for example, tells us to be “fearful when others are greedy, and greedy when others are fearful.” Sir John Templeton taught us to buy excessive pessimism.
Even Baron Rothschild once told investors, “The time to buy is when there’s blood in the streets, even if the blood is your own.”
Some of the top stocks you may want to consider are:
Technical Indicator Convergence: RSI, MACD, and Williams’ %R
1. AbbVie Inc. (NYSE: ABBV) — 3.8% Yield & Technical Reversal Setup
Over the last few weeks, ABBV plunged from about $215 to about $165, where it’s become oversold. It’s also over-extended on RSI, MACD and Williams’ %R. From its current price of $173, we’d like to see it rally back to $200 initially.
Even better, while we wait for the recovery, we can collect its yield of 3.8%. Analysts at Guggenheim also reiterated a buy on the stock with a price target of $214.
2. Bristol Myers Squibb (NYSE: BMY) — FDA Approval & $60 Target Price
BMY recently plummeted from about $60 to $49, also become incredibly oversold.
From its last traded price of $49.23, we’d like to see BMY rally back to $60 initially. Helping, the US FDA just approved the company’s Opdivo plus Yervoy as a treatment for metastatic hepatocellular carcinoma (HCC).
Specifically, the FDA has greenlighted the use of the Opdivo plus Yervoy combination as a first-line option for adults with hepatocellular carcinoma whose cancer cannot be removed or has spread (unresectable or metastatic).
3. Enbridge Inc. (NYSE: ENB) — 6.15% Yield & Energy Demand Outperformance
With a yield of 6.15%, Enbridge (ENB) holds the second-longest natural gas pipeline in the U.S., North America’s longest crude oil pipeline, and a high-growth, renewable power generation business.
Helping, analysts at Citi just initiated a buy rating on the ENB stock, which believes the company is well-positioned to benefit from global energy demands. In addition, as noted by Investing.com, “The firm’s analysts emphasized that Enbridge has consistently exceeded global energy demand growth by 400 basis points, a trend they anticipate will persist.”
While these individual stock opportunities look promising, an even bigger market shift could be just days away — and it’s critical you’re prepared.
Frequently Asked Questions About Buying Oversold Stocks
Q1: What defines an "oversold" stock in technical analysis?
A: A stock is considered oversold when rapid selling pressure pushes its price below its intrinsic technical equilibrium. Indicators like the Relative Strength Index (RSI) dipping below 30 or Williams %R crossing below -80 signal that a stock has fallen too far, too fast, increasing the likelihood of a rebound.
Q2: Why is technical indicator alignment important when buying oversold stocks?
A: Relying on a single technical indicator like RSI can trigger false buy signals during strong downtrends. Aligned signals across multiple indicators (such as RSI, MACD, and Williams %R) provide stronger confirmation of momentum reversals.
Q3: How does dividend yield help protect downside risk in oversold stocks?
A: High-quality companies paying sustainable dividends—such as Enbridge's 6.15% yield or AbbVie's 3.8% yield—provide investors with steady passive cash flow while waiting for capital appreciation and stock price recovery.
Found this helpful? Share it with others.
Written by Ian Cooper